Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

465.81 +5.27 (+1.15%)

Streaming Delayed Price Updated: 1:14 PM EST, Nov 18, 2025 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	287,184
Open	458.15
Bid (Size)	465.31 (120)
Ask (Size)	466.53 (280)
Prev. Close	460.54
Today's Range	456.27 - 469.11
52wk Range	205.87 - 495.55
Shares Outstanding	118,847,693
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Novo Nordisk's $100 Million Coramitug Shows Promise In Reducing Heart Failure Biomarker ↗

November 12, 2025

Novo Nordisk's Coramitug cut NT-proBNP levels and was well tolerated in a Phase 2 ATTR-CM trial, paving the way for its Phase 3 CLEOPATTRA study.

Via Benzinga

Got $5,000? 3 Top Growth Stocks to Buy That Could Double Your Money ↗

November 11, 2025

No investment is a slam dunk to double your money. But these great stocks appear to have what it takes.

Via The Motley Fool

Performance

YTD	+99.4%	+99.4%
1 Month	-5.2%	-5.2%
3 Month	+2.0%	+2.0%
6 Month	+59.6%	+59.6%
1 Year	+100.5%	+100.5%

More News

Healthcare Sector Navigates Turbulent Waters: Innovation Surges Amidst Political Headwinds

November 10, 2025

Via MarketMinute

Earnings Scheduled For October 30, 2025 ↗

October 30, 2025

Via Benzinga

New Post Hoc Analysis from the HELIOS-B Phase 3 Study Shows Vutrisiran Improved Measures of Heart Structure and Function in Patients with ATTR-CM

November 08, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Here's How Much $1000 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth Today ↗

November 07, 2025

Via Benzinga

Intellia Therapeutics Crashes After A Patient In Its Pivotal Study Dies ↗

November 07, 2025

Via Investor's Business Daily

What Does the Market Think About Alnylam Pharmaceuticals Inc? ↗

November 06, 2025

Via Benzinga

Alnylam to Webcast Presentations at Upcoming November Investor Conferences

November 04, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet ↗

November 02, 2025

Via Benzinga

Why Is Alnylam Pharmaceuticals Stock Trading Lower Thursday? ↗

October 30, 2025

Via Benzinga

Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) Stock Dips Despite Blowout Q3 2025 Earnings ↗

October 30, 2025

Via Chartmill

Meta Tumbles 10%, Google Marks Historic Rally: What's Moving Markets Thursday? ↗

October 30, 2025

Via Benzinga

Alnylam Stock Has Already Doubled In 2025. Why It Could Rocket Again On Earnings. ↗

October 30, 2025

Via Investor's Business Daily

Alnylam Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Period Progress

October 30, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Uncovering Potential: Alnylam Pharmaceuticals's Earnings Preview ↗

October 29, 2025

Via Benzinga

Intellia Freezes Key Trial After Serious Liver Event, Stock Tumbles ↗

October 27, 2025

Via Benzinga

Peering Into Alnylam Pharmaceuticals Inc's Recent Short Interest ↗

October 21, 2025

Via Benzinga

Alnylam to Webcast Conference Call Discussing Third Quarter 2025 Financial Results

October 16, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

$1000 Invested In Alnylam Pharmaceuticals 10 Years Ago Would Be Worth This Much Today ↗

October 14, 2025

Via Benzinga

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet ↗

October 11, 2025

Via Benzinga

Ionis Pharmaceuticals (NASDAQ:IONS) Ascends to Six-Year High, Fueled by Breakthrough Pipeline and Robust Sales Outlook

October 08, 2025

Via MarketMinute

ALNYLAM PHARMACEUTICALS INC (NASDAQ:ALNY) Shows Strong Technical Setup for Potential Breakout ↗

October 07, 2025

Via Chartmill

27 Analysts Assess Alnylam Pharmaceuticals: What You Need To Know ↗

October 06, 2025

Via Benzinga

Alnylam Announces First Patient Dosed in ZENITH Global Phase 3 Cardiovascular Outcomes Trial of Zilebesiran

October 01, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Frequently Asked Questions

Is Alnylam Pharmaceuticals, Inc. - Common Stock publicly traded?

Yes, Alnylam Pharmaceuticals, Inc. - Common Stock is publicly traded.

What exchange does Alnylam Pharmaceuticals, Inc. - Common Stock trade on?

Alnylam Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Alnylam Pharmaceuticals, Inc. - Common Stock?

The ticker symbol for Alnylam Pharmaceuticals, Inc. - Common Stock is ALNY on the Nasdaq Stock Market

What is the current price of Alnylam Pharmaceuticals, Inc. - Common Stock?

The current price of Alnylam Pharmaceuticals, Inc. - Common Stock is 465.81

When was Alnylam Pharmaceuticals, Inc. - Common Stock last traded?

The last trade of Alnylam Pharmaceuticals, Inc. - Common Stock was at 11/18/25 01:14 PM ET

What is the market capitalization of Alnylam Pharmaceuticals, Inc. - Common Stock?

The market capitalization of Alnylam Pharmaceuticals, Inc. - Common Stock is 55.36B

How many shares of Alnylam Pharmaceuticals, Inc. - Common Stock are outstanding?

Alnylam Pharmaceuticals, Inc. - Common Stock has 55B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.